Teva Q3 revenue falls 2% as generics decline
Teva reported a 2% decline in Q3 revenue as generics declined.
Related stories
ACB: trading halted on Nasdaq — news pending (8:25 AM ET)
Nasdaq halted trading in ACB (news pending) at 8:25 AM ET.
L impact | EQUITY | Nov 03, 2026, 01:25 PM UTC
OGI: trading halted on Nasdaq — news pending (8:25 AM ET)
Nasdaq halted trading in OGI (news pending) at 8:25 AM ET.
L impact | EQUITY | Nov 03, 2026, 01:25 PM UTC
UFG: Nasdaq trading halt continues — reason not given (8:25 AM ET)
Nasdaq kept trading halted in UFG (reason not given) at 8:25 AM ET.
L impact | EQUITY | Nov 03, 2026, 01:25 PM UTC
NexPoint Residential Q3 Revenue Slightly Beats Estimates as Net Loss Widens
M impact | EQUITY | Nov 03, 2026, 01:25 PM UTC
Ash-Sharqiyah Development Reports Quarterly Loss of 5.4 Million Riyals
M impact | EQUITY | Nov 03, 2026, 01:24 PM UTC
US API Crude Stock Change
L impact | EQUITY | Nov 03, 2026, 01:23 PM UTC